Evaluation of Metal-conjugated Compounds As Inhibitors of 3CL Protease of SARS-CoV

Overview

Journal FEBS Lett

Specialty Biochemistry

Date 2004 Sep 11

PMID 15358550

Citations 56

Authors

John T-A Hsu

Chih-Jung Kuo

Hsing-Pang Hsieh

Yeau-Ching Wang

Kuo-Kuei Huang

Coney P-C Lin

Ping-fang Huang

Xin Chen

Po-Huang Liang

Affiliations

Soon will be listed here.

Abstract

3C-like (3CL) protease is essential for the life cycle of severe acute respiratory syndrome-coronavirus (SARS-CoV) and therefore represents a key anti-viral target. A compound library consisting of 960 commercially available drugs and biologically active substances was screened for inhibition of SARS-CoV 3CL protease. Potent inhibition was achieved using the mercury-containing compounds thimerosal and phenylmercuric acetate, as well as hexachlorophene. As well, 1-10 microM of each compound inhibited viral replication in Vero E6 cell culture. Detailed mechanism studies using a fluorescence-based protease assay demonstrated that the three compounds acted as competitive inhibitors (Ki=0.7, 2.4, and 13.7 microM for phenylmercuric acetate, thimerosal, and hexachlorophene, respectively). A panel of metal ions including Zn2+ and its conjugates were then evaluated for their anti-3CL protease activities. Inhibition was more pronounced using a zinc-conjugated compound (1-hydroxypyridine-2-thione zinc; Ki=0.17 microM) than using the ion alone (Ki=1.1 microM).

Citing Articles

Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: A comprehensive review.

Li X, Song Y Eur J Med Chem. 2023; 260:115772.

PMID: 37659195 PMC: 10529944. DOI: 10.1016/j.ejmech.2023.115772.

A Prototype Assay Multiplexing SARS-CoV-2 3CL-Protease and Angiotensin-Converting Enzyme 2 for Saliva-Based Diagnostics in COVID-19.

Suresh V, Sheik D, Detomasi T, Zhao T, Zepeda T, Saladi S Biosensors (Basel). 2023; 13(7).

PMID: 37504081 PMC: 10377347. DOI: 10.3390/bios13070682.

The Mechanisms of Zinc Action as a Potent Anti-Viral Agent: The Clinical Therapeutic Implication in COVID-19.

Prasad A, Malysa A, Bepler G, Fribley A, Bao B Antioxidants (Basel). 2022; 11(10).

PMID: 36290585 PMC: 9598180. DOI: 10.3390/antiox11101862.

Potential medicinal plants involved in inhibiting 3CL activity: A practical alternate approach to combating COVID-19.

Yang F, Jiang X, Tariq A, Sadia S, Ahmed Z, Sardans J J Integr Med. 2022; 20(6):488-496.

PMID: 35985974 PMC: 9359926. DOI: 10.1016/j.joim.2022.08.001.

Zinc pyrithione is a potent inhibitor of PL and cathepsin L enzymes with inhibition of SARS-CoV-2 entry and replication.

Kladnik J, Dolinar A, Kljun J, Perea D, Grau-Exposito J, Genesca M J Enzyme Inhib Med Chem. 2022; 37(1):2158-2168.

PMID: 35943189 PMC: 9367663. DOI: 10.1080/14756366.2022.2108417.

References

Ksiazek T, Erdman D, Goldsmith C, Zaki S, Peret T, Emery S . A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med. 2003; 348(20):1953-66. DOI: 10.1056/NEJMoa030781. View

Zhang X, Yap Y . Old drugs as lead compounds for a new disease? Binding analysis of SARS coronavirus main proteinase with HIV, psychotic and parasite drugs. Bioorg Med Chem. 2004; 12(10):2517-21. PMC: 7126105. DOI: 10.1016/j.bmc.2004.03.035. View

Fan K, Wei P, Feng Q, Chen S, Huang C, Ma L . Biosynthesis, purification, and substrate specificity of severe acute respiratory syndrome coronavirus 3C-like proteinase. J Biol Chem. 2003; 279(3):1637-42. PMC: 7980035. DOI: 10.1074/jbc.M310875200. View

Cory A, Owen T, BARLTROP J, CORY J . Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun. 1991; 3(7):207-12. DOI: 10.3727/095535491820873191. View

Bacha U, Barrila J, Velazquez-Campoy A, Leavitt S, Freire E . Identification of novel inhibitors of the SARS coronavirus main protease 3CLpro. Biochemistry. 2004; 43(17):4906-12. DOI: 10.1021/bi0361766. View

Brewer G, Johnson V, DICK R, Hedera P, Fink J, Kluin K . Treatment of Wilson's disease with zinc. XVII: treatment during pregnancy. Hepatology. 2000; 31(2):364-70. DOI: 10.1002/hep.510310216. View

Anand K, Palm G, Mesters J, Siddell S, Ziebuhr J, Hilgenfeld R . Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra alpha-helical domain. EMBO J. 2002; 21(13):3213-24. PMC: 126080. DOI: 10.1093/emboj/cdf327. View

Fouchier R, Kuiken T, Schutten M, van Amerongen G, van Doornum G, van den Hoogen B . Aetiology: Koch's postulates fulfilled for SARS virus. Nature. 2003; 423(6937):240. PMC: 7095368. DOI: 10.1038/423240a. View

Jenwitheesuk E, Samudrala R . Identifying inhibitors of the SARS coronavirus proteinase. Bioorg Med Chem Lett. 2003; 13(22):3989-92. PMC: 7119134. DOI: 10.1016/j.bmcl.2003.08.066. View

10.

Hsu J, Kuo C, Hsieh H, Wang Y, Huang K, Lin C . Evaluation of metal-conjugated compounds as inhibitors of 3CL protease of SARS-CoV. FEBS Lett. 2004; 574(1-3):116-20. PMC: 7134601. DOI: 10.1016/j.febslet.2004.08.015. View

11.

Kuo C, Chi Y, Hsu J, Liang P . Characterization of SARS main protease and inhibitor assay using a fluorogenic substrate. Biochem Biophys Res Commun. 2004; 318(4):862-7. PMC: 7134607. DOI: 10.1016/j.bbrc.2004.04.098. View

12.

Wu C, Jan J, Ma S, Kuo C, Juan H, Cheng Y . Small molecules targeting severe acute respiratory syndrome human coronavirus. Proc Natl Acad Sci U S A. 2004; 101(27):10012-7. PMC: 454157. DOI: 10.1073/pnas.0403596101. View

13.

Drosten C, Gunther S, Preiser W, van der Werf S, Brodt H, Becker S . Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 2003; 348(20):1967-76. DOI: 10.1056/NEJMoa030747. View

14.

Wu H, Hsieh Y, Su I, Lin T, Chiu S, Hsu Y . Early detection of antibodies against various structural proteins of the SARS-associated coronavirus in SARS patients. J Biomed Sci. 2004; 11(1):117-26. PMC: 7089234. DOI: 10.1007/BF02256554. View

15.

Anand K, Ziebuhr J, Wadhwani P, Mesters J, Hilgenfeld R . Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science. 2003; 300(5626):1763-7. DOI: 10.1126/science.1085658. View

16.

Basak A, Toure B, Lazure C, Mbikay M, Chretien M, Seidah N . Enzymic characterization in vitro of recombinant proprotein convertase PC4. Biochem J. 1999; 343 Pt 1:29-37. PMC: 1220520. View

17.

Merluzzi V, Cipriano D, McNeil D, Fuchs V, Supeau C, Rosenthal A . Evaluation of zinc complexes on the replication of rhinovirus 2 in vitro. Res Commun Chem Pathol Pharmacol. 1989; 66(3):425-40. View

18.

Yang H, Yang M, Ding Y, Liu Y, Lou Z, Zhou Z . The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. Proc Natl Acad Sci U S A. 2003; 100(23):13190-5. PMC: 263746. DOI: 10.1073/pnas.1835675100. View

19.

Wu C, Jan J, Chen C, Hsieh H, Hwang D, Liu H . Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide. Antimicrob Agents Chemother. 2004; 48(7):2693-6. PMC: 434198. DOI: 10.1128/AAC.48.7.2693-2696.2004. View

20.

Korant B, Kauer J, Butterworth B . Zinc ions inhibit replication of rhinoviruses. Nature. 1974; 248(449):588-90. DOI: 10.1038/248588a0. View